Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Abroad (travel likely)RecruitingPHASE2

Conditions

Ovarian Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Memorial Sloan Kettering Cancer Center, New York, New York, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Amir Jazaeri, MD) · aajazaeri@mdanderson.org · 713-745-1613
Contact: Principal Investigator (Amir Jazaeri, MD)

Study leads

Amir Jazaeri, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Ovarian Cancer Recurrent

IsraelRecruitingPHASE1, PHASE2

New Haven, United States · Louisville, United States

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Pancreatic Cancer · Renal Cell Cancer · Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · La Jolla, United States

A Beta-only IL-2 ImmunoTherapY Study

Advanced Solid Tumor · Unresectable Solid Tumor · Clear Cell Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

San Diego, United States · San Francisco, United States